Home/Filings/4/0001209191-22-056444
4//SEC Filing

SCHNEIDER PHILLIP M 4

Accession 0001209191-22-056444

CIK 0001671858other

Filed

Nov 9, 7:00 PM ET

Accepted

Nov 10, 6:00 PM ET

Size

9.2 KB

Accession

0001209191-22-056444

Insider Transaction Report

Form 4
Period: 2022-11-08
Transactions
  • Award

    Stock option (right to buy)

    2022-11-08+76,82376,823 total
    Exercise: $1.44Exp: 2031-12-14Common Stock (76,823 underlying)
  • Award

    Stock option (right to buy)

    2022-11-08+153,647153,647 total
    Exercise: $0.84Exp: 2029-07-05Common Stock (153,647 underlying)
Footnotes (5)
  • [F1]25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
  • [F2]Received in exchange for a stock option to acquire 130,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $0.99 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement").
  • [F3]Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.
  • [F4]The shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date.
  • [F5]Received in exchange for a stock option to acquire 65,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement.

Issuer

ARS Pharmaceuticals, Inc.

CIK 0001671858

Entity typeother

Related Parties

1
  • filerCIK 0001230051

Filing Metadata

Form type
4
Filed
Nov 9, 7:00 PM ET
Accepted
Nov 10, 6:00 PM ET
Size
9.2 KB